{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:25Z","timestamp":1793228245400,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","award":["OICR IA-016"],"award-info":[{"award-number":["OICR IA-016"]}],"id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000092","name":"Ontario Genomics Institute","doi-asserted-by":"publisher","award":["OGI-125"],"award-info":[{"award-number":["OGI-125"]}],"id":[{"id":"10.13039\/501100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 145586"],"award-info":[{"award-number":["MOP 145586"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 487005"],"award-info":[{"award-number":["MOP 487005"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019711","name":"London Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000023","name":"Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000241","name":"Physicians&apos; Services Incorporated Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xcrm.2026.102820","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:40:04Z","timestamp":1778859604000},"page":"102820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-8236","authenticated-orcid":false,"given":"Peter Y.F.","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalna","family":"Meens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jarycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice E.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushfiq H.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshman","family":"Gunaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe S.","family":"Mymryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Ailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102820_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling Pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF - a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib3","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-25-0057","article-title":"Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma","volume":"14","author":"Karimi","year":"2025","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.xcrm.2026.102820_bib4","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1002\/cncr.24416","article-title":"Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005","volume":"115","author":"Chen","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2026.102820_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.xcrm.2026.102820_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113826","article-title":"The genomic and evolutionary landscapes of anaplastic thyroid carcinoma","volume":"43","author":"Zeng","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102820_bib7","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102820_bib8","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102820_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg2538","article-title":"Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident","volume":"372","author":"Morton","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102820_bib10","doi-asserted-by":"crossref","first-page":"viii645","DOI":"10.1093\/annonc\/mdy302.002","article-title":"Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E\u2013mutated anaplastic thyroid cancer (ATC)","volume":"29","author":"Keam","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib11","first-page":"1184","article-title":"Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.xcrm.2026.102820_bib12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/thy.2019.0514","article-title":"Acquired Secondary RAS Mutation in BRAF(V600E)-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors","volume":"30","author":"Cabanillas","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.xcrm.2026.102820_bib13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102820_bib14","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1172\/JCI120966","article-title":"Hgf\/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers","volume":"128","author":"Knauf","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102820_bib15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrc.2017.79","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102820_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102820_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cell.2018.04.012","article-title":"An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential","volume":"173","author":"Wang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib18","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102820_bib19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102820_bib20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102820_bib21","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102820_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102820_bib26","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-20-0735","article-title":"SWI\/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies","volume":"11","author":"Saqcena","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102820_bib27","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107764","article-title":"Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers","volume":"31","author":"Ozkan-Dagliyan","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102820_bib29","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS(G12C) Inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102820_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102820_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK Pathway in KRAS-Driven Tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102820_bib34","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102820_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","article-title":"An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling","volume":"30","author":"Karoulia","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib37","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","article-title":"Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers","volume":"28","author":"Peng","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib38","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/2159-8290.CD-20-1351","article-title":"Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling","volume":"11","author":"Adamopoulos","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102820_bib39","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1158\/0008-5472.CAN-13-1825","article-title":"Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma","volume":"73","author":"Nakamura","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib40","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","article-title":"LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors","volume":"27","author":"Monaco","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104634","article-title":"Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib","volume":"299","author":"Tkacik","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102820_bib42","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","article-title":"Phase I, Open-Label, Dose-Escalation\/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors","volume":"38","author":"Desai","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102820_bib44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102820_bib45","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study","volume":"41","author":"de Braud","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","article-title":"EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt","volume":"16","author":"Miao","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib47","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.surg.2012.08.041","article-title":"Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt","volume":"152","author":"O\u2019Malley","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.xcrm.2026.102820_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1089\/thy.2019.0728","article-title":"Serine 897 phosphorylation of EPHA2 is involved in signaling of oncogenic ERK1\/2 drivers in thyroid cancer cells","volume":"31","author":"Allocca","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.xcrm.2026.102820_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108765","article-title":"Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1\/STAT3 and AKT signaling","volume":"34","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.102820_bib50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/2159-8290.CD-14-0295","article-title":"EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma","volume":"5","author":"Miao","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102820_bib51","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-021-00967-z","article-title":"Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers","volume":"53","author":"Ito","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102820_bib52","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1038\/sj.onc.1210412","article-title":"Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases","volume":"26","author":"Owens","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2026.102820_bib53","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3390\/cancers13194985","article-title":"Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis","volume":"13","author":"Usman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102820_bib54","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.oraloncology.2012.05.011","article-title":"Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformation","volume":"48","author":"Chaw","year":"2012","journal-title":"Oral Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","article-title":"Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap","volume":"14","author":"Reimand","year":"2019","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102820_bib56","doi-asserted-by":"crossref","first-page":"W307","DOI":"10.1093\/nar\/gkr378","article-title":"Profiler--a web server for functional interpretation of gene lists (2011 update)","volume":"39","author":"Reimand","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/thy.2013.0483","article-title":"The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma","volume":"24","author":"Vanden Borre","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.xcrm.2026.102820_bib58","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03515-1","article-title":"ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma","volume":"594","author":"Yen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102820_bib59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccell.2018.06.012","article-title":"MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation","volume":"34","author":"Jin","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib60","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting EphA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11033-024-09298-8","article-title":"Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatment","volume":"51","author":"Nehal","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.xcrm.2026.102820_bib62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40463-022-00558-w","article-title":"Introduction and expression of PIK3CA(E545K) in a papillary thyroid cancer BRAF(V600E) cell line leads to a dedifferentiated aggressive phenotype","volume":"51","author":"Pinto","year":"2022","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.xcrm.2026.102820_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib64","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib65","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib66","doi-asserted-by":"crossref","first-page":"D1083","DOI":"10.1093\/nar\/gkaa968","article-title":"CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics","volume":"49","author":"Luna","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib67","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and accurate long-read alignment with Burrows-Wheeler transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102820_bib68","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1101\/gr.180281.114","article-title":"TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data","volume":"24","author":"Ha","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2026.102820_bib69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41596-023-00913-9","article-title":"CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction","volume":"19","author":"Grigoriadis","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2026.102820_bib70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13015-021-00181-w","article-title":"Fast lightweight accurate xenograft sorting","volume":"16","author":"Zentgraf","year":"2021","journal-title":"Algorithms Mol. Biol."},{"key":"10.1016\/j.xcrm.2026.102820_bib71","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102820_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102820_bib73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.102820_bib74","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2026.102820_bib75","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2026.102820_bib76","article-title":"decoupleR: ensemble of computational methods to infer biological activities from omics data","volume":"2","author":"Badia-I-Mompel","year":"2022","journal-title":"Bioinform. Adv."},{"key":"10.1016\/j.xcrm.2026.102820_bib77","article-title":"Clinical Presentation and Genomic Analysis of HPV-Related Squamous Cell Carcinoma of the Larynx in Two Young Female Patients","volume":"15","author":"Taboun","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.xcrm.2026.102820_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106580","article-title":"Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer","volume":"146","author":"Shaikh","year":"2023","journal-title":"Oral Oncol."},{"key":"10.1016\/j.xcrm.2026.102820_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105629","article-title":"Cohort-level clinical trajectory and molecular landscape of idiopathic subglottic stenosis for precision laryngology\u2014a study of the Canadian airways research (CARE) group","volume":"114","author":"Lin","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2026.102820_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105631","article-title":"Cellular blueprint of healthy and diseased human epiglottis and subglottis\u2014a study of the Canadian Airways Research (CARE) group","volume":"114","author":"Zeng","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2026.102820_bib81","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102820_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s43856-022-00159-8","article-title":"Proteome and phosphoproteome signatures of recurrence for HPV(+) head and neck squamous cell carcinoma","volume":"2","author":"Kaneko","year":"2022","journal-title":"Commun. Med."},{"key":"10.1016\/j.xcrm.2026.102820_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104373","article-title":"Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification","volume":"86","author":"Zeng","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2026.102820_bib84","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/j.gastro.2023.01.002","article-title":"F4\/80(+)Ly6C(high) Macrophages Lead to Cell Plasticity and Cancer Initiation in Colitis","volume":"164","author":"Shin","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2026.102820_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.107061","article-title":"Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer","volume":"159","author":"Dawson","year":"2024","journal-title":"Oral Oncol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:26:59Z","timestamp":1785893219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666379126002375"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102820","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102820"}}